Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Int J Clin Oncol. 2020 Jan;25(1):1-42. doi: 10.1007/s10147-019-01485-z. Epub 2019 Jun 15.
The number of deaths from colorectal cancer in Japan continues to increase. Colorectal cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of treatments was performed, with corrections and additions made based on knowledge acquired since the 2016 version (drug therapy) and the 2014 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum guidelines 2019 for the treatment of colorectal cancer (JSCCR guidelines 2019) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment and to deepen mutual understanding between healthcare professionals and patients by making these guidelines available to the general public. These guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. Controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSCCR guidelines 2019.
日本结直肠癌死亡人数持续增加。2016 年,结直肠癌死亡人数超过 5 万。在 2019 年版中,对治疗的各个方面进行了修订,根据自 2016 年版(药物治疗)和 2014 年版(其他治疗)以来获得的知识进行了修正和补充。为了展示结直肠癌的标准治疗策略,消除机构之间在治疗方面的差异,消除不必要的和不足的治疗,并通过向公众提供这些指南来加深医疗保健专业人员和患者之间的相互理解,制定了 2019 年日本结直肠癌协会(JSCCR)结直肠癌治疗指南(JSCCR 指南 2019)。这些指南是由 JSCCR 指南委员会在仔细审查通过文献检索检索到的证据的基础上达成共识制定的,同时考虑到日本的医疗保险制度和实际临床实践环境。因此,这些指南可以作为实际临床实践中治疗结直肠癌的工具。更具体地说,它们可以作为从患者那里获得知情同意并为每位患者选择治疗方法的指南。选择了有争议的问题作为临床问题,并提出了建议。每个建议都附有证据的分类和根据指南委员会成员达成的共识的推荐类别分类。在这里,我们呈现了 2019 年 JSCCR 指南的英文版。
Zhonghua Wei Chang Wai Ke Za Zhi. 2019-11-25
Int J Clin Oncol. 2018-10-5
Langenbecks Arch Surg. 2025-8-29
J Gastroenterol. 2025-8-22
J Anus Rectum Colon. 2019-10-30
N Engl J Med. 2018-3-29